Cidara Therapeutics, Inc.

Paul Daruwala

Kenneth Bartizal

Voon Ong

Dirk Thye

Taylor Sandison

Balasingam Radhakrishnan

Navdeep Balkrishna Malkar

David Hughes

Anuradha Vaidya

Martin Patrick Hughes

Maureen Roden

Jeffrey Brian Locke

The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.

Compositions and methods for the treatment of fungal infections

The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).

Dosing regimens for treatment of fungal infections

The disclosure relates to methods of prophylactic and therapeutic treatments of ainfection (i.e., an infection caused by) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of aspp. The methods of the disclosure can be useful in immunocompromised subjects.

Methods for preventing and treating pneumocystis infections

The disclosure relates to methods of prophylactic and therapeutic treatments of ainfection (i.e., an infection caused by) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of aspp. The methods of the disclosure can be useful in immunocompromized subjects.

Growing community of inventors

Del Mar, CA, United States of America

Paul Daruwala